Products for Research Use Only

Trag-3

CAT: 0579-X1869BSize: 50 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0579-X1869BSize:50 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Background
The expression of the cancer-testis antigen Taxol resistance-associated gene-3 (TRAG-3) is associated with acquired paclitaxel (Taxol) resistance, and is expressed in a variety of cancers - e.g., breast cancer, leukemia, and melanoma. Overexpressed in taxol-resistant breast cancer line MDA 435(TR) and the doxorubicin-resistant multiple myelanoma lines 8226/Dox(40) and 8226/MDR(10)V. Weakly expressed in kidney. TRAG-3 is an attractive target for immunotherapy of cancer._x000B__x000B_First identified as a novel cancer/testis antigen, TRAG-3, (Taxol Resistance Associated Gene-3) was initially discovered in a search for new genes involved in drug resistance. Early studies of TRAG-3 revealed a minimal to absent expression in normal tissues and a marked over-expression in many carcinoma cell lines including several melanoma lines. By RT-PCR evaluation of TRAG-3 two transcripts are seen in many carcinoma cell lines with products in the the 799 bp and a second alternatively spliced transcript._x000B_
Synonyms
Taxol resistance-associated gene-3
Conjugation
Unconjugated
Type
Blocking Peptide
Applications
Functional Inhibition
Assay Principle
Blocking peptide for use with Trag-3 antibodies (Cat. Nos. X1871P , X1872P).
Stability
See expiration date on vial
Concentration
See vial for Concentration
Form
Provided as solution in phosphate buffered saline with 0,08% sodium azide
Precautions
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving Humans or animals.
Shipping Conditions
Ambient Temperature, freeze upon arrival
Storage Conditions
Product should be stored at -20ºC; Aliquot to avoid freeze/thaw cycles
Functional Analysis
Antibody Function Blocking